Bioscience
Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program
Published in Health Business Week, April 20th, 2007
Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced that the company had begun treating patients in its LUCIDA (LUx Corneal Transplant Implant Development and Advancement of Therapy) pivotal clinical trial program of LX201, the company's cyclosporine A (CsA) eluting silicone matrix implant. The LUCIDA pivotal program, which consists of two controlled studies, is investigating the use of LX201 in patients at elevated immune mediated risk of rejection or graft loss subsequent to cornea transplantation.
Lux Biosciences expects to enroll a total of more than 400 patients across two pivotal protocols. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-04-20)
More Articles from Health Business Week
- Abdominal Pain
New Survey Reveals Women Are Unaware of the Dangers of Surgical Adhesions - ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering - ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Announces Proposed Public Stock Offering - Accuro Healthcare Solutions, Inc.
Accuro Healthcare Solutions Acquires Woodmoor Group - Adaptis
Adaptis Conquers QNXT Bachelor Certification in Record Time - AdCare Health Systems, Inc.
AdCare Health Systems, Inc. Reports Financial Results for 2006 - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
